Skip to content
About
Our Team
Scientific Approach
Our Engineering
Our Platform
Pipeline & Programs
Our Pipeline
GNTI-122
Careers
News
Genti in the News
Publications
Conference Presentations
Contact
Toggle navigation
About
Our Team
Scientific Approach
Our Engineering
Our Platform
Pipeline & Programs
Our Pipeline
GNTI-122
Careers
News
Genti in the News
Publications
Conference Presentations
Contact
Publication & Posters
March 23, 2024
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
Uenishi et al. (2024)
JCI Insights
9
.
6
‹ Back to Publications